Astal Laboratories Ltd

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive grade. Despite recent market headwinds and a downgrade in its Mojo Grade from Buy to Hold, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point for investors seeking value in a challenging environment.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating downgraded from Buy to Hold as of 1 September 2026. This revision reflects a nuanced assessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. While the company continues to demonstrate robust financial growth, recent technical indicators and valuation metrics have prompted a more cautious stance among investors.

Astal Laboratories Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 20 August 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 September 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has seen its valuation parameters shift from very attractive to attractive, reflecting a nuanced change in market perception. With a current price of ₹83.67 and a recent day gain of 2.41%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more balanced valuation compared to its historical and peer averages, prompting investors to reassess its price attractiveness amid steady operational metrics.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating downgraded from Strong Buy to Buy as of 20 Aug 2026. This adjustment reflects a nuanced shift across four key parameters: quality, valuation, financial trend, and technical indicators. While the company posted robust quarterly financials in June 2026, certain valuation and technical signals have moderated the overall outlook, prompting a recalibration of its mojo grade to 74.0.

Astal Laboratories Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by a marked improvement in technical indicators and attractive valuation metrics. Despite flat recent financial performance, the company’s strong debt servicing ability and long-term growth prospects underpin this positive reassessment.

The 50-day moving average has crossed above the 200-day moving average for Astal Laboratories Ltd, signalling a golden cross on 11 Aug 2026. Yet, the broader technical and fundamental picture presents a nuanced story that tempers the enthusiasm this crossover might typically inspire.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 02 August 2026, providing investors with the latest insights into its performance and outlook.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 05 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 July 2026, providing investors with the latest insights into its performance and outlook.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 June 2026, providing investors with the latest insights into its performance and outlook.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astal Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its financial quality, valuation attractiveness, and technical outlook despite a flat recent financial trend. This reassessment comes amid a mixed quarterly performance and evolving market dynamics, positioning the micro-cap stock as a cautious but watchful opportunity for investors.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a significant shift in its valuation parameters, moving from a previously very expensive rating to a very attractive valuation grade. This change comes amid a backdrop of mixed returns and sector challenges, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a notable upgrade in its quality grading from average to good, reflecting improvements in key business fundamentals. Despite this positive shift, the company’s stock performance remains under pressure, with a 4.58% decline on 3 June 2026 and a year-to-date return lagging behind the Sensex. This article analyses the underlying financial metrics driving the quality upgrade and assesses the implications for investors.